According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos, Inc. is based in Boston, Massachusetts. “
Shares of AKUS opened at $3.68 on Thursday. Akouos has a 52-week low of $3.56 and a 52-week high of $16.50. The stock has a fifty day simple moving average of $4.90 and a two-hundred day simple moving average of $7.29.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Akouos by 5.7% during the fourth quarter. BlackRock Inc. now owns 1,985,946 shares of the company’s stock worth $16,881,000 after acquiring an additional 107,296 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Akouos by 1,947.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,980 shares of the company’s stock worth $102,000 after purchasing an additional 11,395 shares during the period. Wexford Capital LP acquired a new stake in shares of Akouos during the 4th quarter worth about $425,000. TCG Crossover Management LLC purchased a new stake in Akouos in the 4th quarter valued at about $8,884,000. Finally, Parametric Portfolio Associates LLC lifted its position in Akouos by 15.5% in the fourth quarter. Parametric Portfolio Associates LLC now owns 87,328 shares of the company’s stock valued at $742,000 after buying an additional 11,695 shares during the last quarter. Hedge funds and other institutional investors own 96.57% of the company’s stock.
About Akouos (Get Rating)
Akouos, Inc, a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.
- Get a free copy of the StockNews.com research report on Akouos (AKUS)
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akouos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akouos and related companies with MarketBeat.com's FREE daily email newsletter.